Media Contact
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday:
- Andrea Greif
Senior Director, Communications
(914) 821-8958
andrea.greif@lls.org
FDA Approval: LLS Applauds New Advance for Acute Lymphoblastic Leukemia
RYE BROOK, N.Y. (August 17, 2017) – The Leukemia & Lymphoma Society (LLS) applauds today’s approval by the U.S. Food and Drug Administration (FDA) of inotuzumab ozogamicin (Besponsa®) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). This year alone, it is estimated that almost 6,000 people in the United States will be diagnosed with ALL. Thi...
More than 20 Years Helping Cancer Patients and Saving Lives
See multimedia release here. RYE BROOK, N.Y. (August 8, 2017) – Where can I get good information about my cancer and treatments? Should I get a second opinion? Is there anyone I can talk with who has been through this? Where can I get financial assistance to help cover the cost of my treatment? How do I talk with my loved ones and children about my disease? These are just a few of the hundreds of questions...
LLS Applauds Another Advance for Blood Cancer Patients
August 3, 2017 (Rye Brook, NY) - The Leukemia & Lymphoma Society (LLS) applauds the U.S. Food and Drug Administration (FDA) approval today of CPX-351 (VyxeosTM), an innovative combination of two chemotherapy drugs being used to treat two high-risk subgroups of acute myeloid leukemia (AML) patients. After more than four decades of little progress in treating AML, this approval marks the third drug appr...
FDA Approves New Targeted Therapy for AML
Rye Brook, N.Y. (August 1, 2017) – Today marks another significant advance in the offensive against acute myeloid leukemia (AML), one of the most deadly blood cancers that takes more than 10,000 lives in the U.S. each year. The Leukemia & Lymphoma Society (LLS) applauds The U.S. Food & Drug Administration’s approval today of a new targeted therapy, enasidenib (IDHIFA®), for patients with AML, who ha...
‘SKINNY’ SENATE HEALTHCARE BILL WOULD THREATEN ACCESS TO CANCER TREATMENT
Rye Brook, N.Y. (July 26, 2017) – The U.S. Senate has initiated debate on the House-passed healthcare bill, and Senate leaders are indicating they intend to advance legislation they have termed ‘skinny repeal.’ This Senate proposal would increase premiums and cost-sharing for patients who purchase their own insurance plans, while leading some insurers to stop selling non-group coverage altogether, according to ...
LLS Announces Expansion of Precision Medicine Approach to Fight Blood Cancer
Rye Brook, NY (July 19, 2017) – The Leukemia & Lymphoma Society (LLS) today announced the expansion of its groundbreaking precision medicine Beat AML® Master Trial, to test new, investigational treatments for acute myeloid leukemia (AML), the central initiative of LLS’s comprehensive assault on this deadly blood cancer affecting 20,000 Americans annually. Launched in October 2016, the master trial has exc...
Man & Woman of the Year is Proof Individuals can Impact Cancer Cures
View multimedia release here. Rye Brook, NY (July 13, 2017) – As the leader in peer-to-peer fundraising for almost 70 years, The Leukemia & Lymphoma Society (LLS) continues to find ways to reinvent the way health charities raise vital funds for research and patient support. After pioneering non-profit sports training with Team In Training, LLS turned the traditional walk into a community experienc...
Senate Health Bill Puts Cancer Care Out of Reach for Many
Patients Would Face New Financial Barriers to Life-Saving Treatment Rye Brook, N.Y. (June 23, 2017) – The Senate’s Better Care Reconciliation Act would exacerbate the financial and bureaucratic barriers that stand between cancer patients and life-saving treatments, based on an analysis by The Leukemia & Lymphoma Society (LLS). Below is a statement from Louis J. DeGennaro, Ph.D.,...